Brain Stem Neoplasm clinical trials at UCSF
1 research study open to eligible people

• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

  open to eligible people ages 12 months to 21 years

  This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

  San Francisco, California and other locations

Last updated: March 15, 2019